National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

The Children's Vaccine Initiative: Continuing Activities (1995)
Institute of Medicine (IOM)

Citation Manager

. "A ROLE FOR INDUSTRY." The Children's Vaccine Initiative: Continuing Activities. Washington, DC: The National Academies Press, 1995.

Please select a format:

BibTeX EndNote RefMan


Page
33
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


The Children’s Vaccine Initiative: Continuing Activities: A Summary of Two Workshops Held September 12–13 and October 25–26, 1994

TABLE 6 Possible UNICEF–Industry Partnerships

 

Research

Development

Scale-Up

Description

Supplier conducts research

We provide financial support

Cooperate to develop vaccine

We support clinical trial work

We solicit government support

Supplier provides vaccine and expertise

Supplier scales-up vaccine

Suppliers

One to many

One to many

One

Selection Criteria

Research plan and research skill of supplier

Vaccine performance, development plan, and development skill of supplier

Vaccine approval, price

Terms

Joint funding of research

Supplier controls decision-making on IPRs

Supplier has first option to proceed with research; if it declines, we can go elsewhere

Supplier commits to cost-plus pricing if/when vaccine is launched

Supplier funds development activity UNICEF receives right to purchase vaccine at cost plus if/when developed

Supplier incurs cost of scale-up and production

Volume, Price Obligation

None

None

UNICEF and supplier agree to specific price/volume commitments

Assuming vaccine meets minimum performance and quality characteristics

NOTE: IPR = intellecutal property rights.

SOURCE: UNICEF, 1994

Page
33